Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.
The objective of this study is to investigate the prevalence of elevated lipoprotein(a) concentrations and distribution of lipoprotein(a) in a working general population. This is a prospective study investigating the association of lipoprotein(a) with cardiovascular markers and outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Working General Population | Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Distribution and prevalence of elevated Lipoprotein(a) | Investigate the distribution lipoprotein(a) and prevalence of elevated lipoprotein(a) concentrations in various ethnicities. | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of lipoprotein(a) with cardiovascular outcomes | Observational study to assess the correlation of degree of elevation of lipoprotein(a) with cardiovascular outcomes prospectively. | 10 years |
| Genetic variants of lipoprotein(a) and cardiovascular outcomes atherosclerotic events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Working general population
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Loh Wann Jia | Singhealth Foundation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Trials & Research Unit | Singapore | Singapore | 529889 | Singapore |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36468313 | Background | Loh WJ, Watts GF. Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle? Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):94-102. doi: 10.1097/MED.0000000000000789. Epub 2022 Dec 5. | |
| 34887076 | Background | Loh WJ, Chang X, Aw TC, Phua SK, Low AF, Chan MY, Watts GF, Heng CK. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis. 2022 May;349:160-165. doi: 10.1016/j.atherosclerosis.2021.11.018. Epub 2021 Nov 26. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| C563617 | Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia |
| D002318 | Cardiovascular Diseases |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood are collected to measure lipoprotein(a) concentrations, genetic variants and biomarkers.
Assess the association of genetic variants of lipoprotein(a) with the measured lipoprotein(a) concentrations in various ethnicities, and prospectively assess the association of these genetic variants with cardiovascular outcomes |
| 10 years |
| 35571022 | Background | Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022. |
| 36108076 | Background | Nestel P, Loh WJ, Ward NC, Watts GF. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4281-e4294. doi: 10.1210/clinem/dgac541. |
| 36036785 | Background | Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgozoglu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. |
| 41792760 | Derived | Loh WJ, Tun MH, Shak B, Phua SK, Lim G, Yap C, Khoo J, Puar T, Heng CK, Foo R, Watts GF, Dalan R, Aw TC. Lipoprotein(a), apolipoprotein B and other lipid biomarkers in Asian healthcare workers. Lipids Health Dis. 2026 Mar 6;25(1):88. doi: 10.1186/s12944-026-02912-7. |
| D009750 |
| Nutritional and Metabolic Diseases |